Morgan Stanley Maintains Hologic to Equal-weight with Price Target $40.00

Brokerage firm Morgan Stanley Maintains its rating on Hologic(NASDAQ:HOLX). In a research note issued to the investors, the brokerage major Raises the price-target to $40.00 per share. The shares have been rated Equal-weight. The rating by Morgan Stanley was issued on Jul 28, 2016.

In a different note, On Jul 28, 2016, Jefferies said it Maintains its rating on Hologic. In the research note, the firm Raises the price-target to $42.00 per share. The shares have been rated ‘Buy’ by the firm. On Jul 28, 2016, Evercore ISI Group said it Upgrades its rating on Hologic. The shares have been rated ‘Buy’ by the firm.

Hologic (HOLX) shares turned negative on Thursdays trading session with the shares closing down -0.32 points or -0.82% at a volume of 20,65,500. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $39.15. The peak price level was also seen at $39.15 while the days lowest was $38.01. Finally the shares closed at $38.68. The 52-week high of the shares is $43 while the 52-week low is $31.84. According to the latest information available, the market cap of the company is $10,731 M.

Hologic(HOLX) last announced its earnings results on Jul 27, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $717.40M. Analysts had an estimated revenue of $704.27M. Earnings per share were $0.51. Analysts had estimated an EPS of $0.48.

Several Insider Transactions has been reported to the SEC. On Jul 25, 2016, Sally Crawford (director) sold 16,071 shares at $37.00 per share price.Also, On Jul 25, 2016, Nancy Leaming (director) sold 8,179 shares at $37.00 per share price.On Jun 2, 2016, Lawrence M Levy (director) sold 17,794 shares at $34.41 per share price, according to the Form-4 filing with the securities and exchange commission.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.